RegulyzeBifidobacterium breve
Bifidobacterium breve is a probiotic strain permitted for use in nutraceuticals and health supplements under India's FSSAI framework. Regulyze tracks its regulatory status, limits and label requirements across regulatory frameworks.
Regulatory status
| Framework | Status | Limit | Source | Last reviewed |
|---|---|---|---|---|
| India — FSSAI | Permitted | As specified / GMP | FSS (Health Supplements, Nutraceuticals…) Regulations 2022 | 2026-06-20 |
Coverage for the USA (FDA), EU (EFSA), UK, GCC and ASEAN is being added — this page updates automatically as frameworks are assessed.
About Bifidobacterium breve
Bifidobacterium breve is tracked in the Regulyze Ingredient Intelligence database as a probiotic strain. The regulatory details on this page are generated from Regulyze's structured regulatory dataset and are reviewed against the cited source.
Frequently asked questions
Is Bifidobacterium breve permitted in nutraceuticals under FSSAI (India)?
Bifidobacterium breve is currently permitted for use in health supplements and nutraceuticals under India's FSSAI framework, per FSS (Health Supplements, Nutraceuticals…) Regulations 2022. Always verify against the current official regulation for your product and market.
What is the permitted dosage of Bifidobacterium breve?
No single numeric limit is listed in the source for Bifidobacterium breve; permitted use is at GMP or as specified. Confirm against the current regulation.
What product category does Bifidobacterium breve belong to?
Bifidobacterium breve is classified under: Probiotics.
Source: FSS (Health Supplements, Nutraceuticals…) Regulations 2022 · Last reviewed: 2026-06-20 · Data version: db-2026-06-20. Indicative only — verify against the current official regulation before use.